Verrica Pharmaceuticals Inc.(简称:Verrica)宣布,公司预计将于2026年中期与Torii Pharmaceutical合作,在美国和日本启动其候选药物Ycanth的第二项3期临床试验。这一进展标志着Ycanth在治疗领域的开发进程迈出重要一步,为后续市场拓展奠定基础。
Verrica Pharmaceuticals Inc.(简称:Verrica)宣布,公司预计将于2026年中期与Torii Pharmaceutical合作,在美国和日本启动其候选药物Ycanth的第二项3期临床试验。这一进展标志着Ycanth在治疗领域的开发进程迈出重要一步,为后续市场拓展奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.